Ulrich Herrlinger

Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas

Karen S. Aboody, Alice B. Brown, Nikolai G. Rainov et al. · Proceedings of the National Academy of Sciences · 2000 · 1.2K citations · Full text

Life Sciences, Neuroscience, Oncology +16

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp, Monika E. Hegi, Thierry Gorlia et al. · The Lancet Oncology · 2014 · 1K citations

Medicine, Oncology, Pharmacotherapy +14

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

Eckhard Thiel, Agnieszka Korfel, Peter Martus et al. · The Lancet Oncology · 2010 · 622 citations

Medicine, Oncology, Pharmacotherapy +10

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 576 citations · Full text

Medicine, Oncology, Pharmacology +16

SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells<b><i>In vitro</i></b>and<b><i>In vivo</i></b>

Martin Uhl, Steffen Aulwurm, Jörg Wischhusen et al. · Cancer Research · 2004 · 412 citations · Full text

Medicine, Cancer Biology, Oncology +17